Technical Analysis for CRBU - Caribou Biosciences, Inc.

Grade Last Price % Change Price Change
D 1.96 -1.51% -0.03
CRBU closed down 1.51 percent on Wednesday, November 20, 2024, on 1.84 times normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Bullish Engulfing Bullish -1.51%
NR7 Range Contraction -1.51%
Wide Bands Range Expansion -1.51%
Oversold Stochastic Weakness -1.51%
50 DMA Resistance Bearish -1.01%
Doji - Bullish? Reversal -1.01%
Stochastic Reached Oversold Weakness -1.01%

   Recent Intraday Alerts

Alert Time
50 DMA Resistance about 21 hours ago
Rose Above Previous Day's High about 21 hours ago
Rose Above 50 DMA about 21 hours ago
1.5x Volume Pace about 21 hours ago
Up 3% about 21 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Caribou Biosciences, Inc. Description

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Solid Tumors Cancer Immunotherapy Cell Therapy Cell Biology Leukemia Multiple Myeloma Breakthrough Therapy Hematologic Malignancies Chimeric Antigen Receptor T Cell T Cells CD19 Refractory Acute Myeloid Leukemia Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia

Is CRBU a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.33
52 Week Low 1.5
Average Volume 1,212,842
200-Day Moving Average 3.21
50-Day Moving Average 2.05
20-Day Moving Average 2.20
10-Day Moving Average 2.28
Average True Range 0.21
RSI (14) 42.53
ADX 21.33
+DI 21.80
-DI 20.50
Chandelier Exit (Long, 3 ATRs) 2.36
Chandelier Exit (Short, 3 ATRs) 2.41
Upper Bollinger Bands 2.86
Lower Bollinger Band 1.54
Percent B (%b) 0.32
BandWidth 60.43
MACD Line 0.01
MACD Signal Line 0.08
MACD Histogram -0.0663
Fundamentals Value
Market Cap 173.32 Million
Num Shares 88.4 Million
EPS -1.43
Price-to-Earnings (P/E) Ratio -1.37
Price-to-Sales 17.71
Price-to-Book 1.51
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.22
Resistance 3 (R3) 2.23 2.15 2.17
Resistance 2 (R2) 2.15 2.09 2.15 2.16
Resistance 1 (R1) 2.06 2.05 2.02 2.05 2.14
Pivot Point 1.98 1.98 1.97 1.98 1.98
Support 1 (S1) 1.89 1.92 1.85 1.88 1.78
Support 2 (S2) 1.81 1.88 1.81 1.76
Support 3 (S3) 1.72 1.81 1.75
Support 4 (S4) 1.71